Efficacy of a Human Amniotic Tissue-derived Allograft, NuCel, in Patients Undergoing Posteriolateral Lumbar Fusions for Degenerative Disc Disease

Next Previous
Trial Profile

Efficacy of a Human Amniotic Tissue-derived Allograft, NuCel, in Patients Undergoing Posteriolateral Lumbar Fusions for Degenerative Disc Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs Amniotic cell therapy-NuCel (Primary)
  • Indications Intervertebral disc degeneration; Spondylosis
  • Focus Therapeutic Use

    • Most Recent Events

    • 14 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 13 Oct 2016 Status changed from recruiting to active, no longer recruiting.
    • 28 Mar 2016 Planned End Date changed from 1 Feb 2016 to 1 Feb 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top